Lv2
120 积分 2024-04-17 加入
[Expert consensus on immunotherapy for small cell lung cancer (2025 edition)]
22天前
已完结
Targeting PI3K/AKT/mTOR Signaling to Overcome Drug Resistance in Cancer
26天前
已完结
Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer
27天前
已完结
Integrative genomic analysis of DLBCL identifies immune environments associated with bispecific antibody response
1个月前
已完结
Integrative genomic analysis of DLBCL identifies immune environments associated with bispecific antibody response
1个月前
已关闭
Integrative genomic analysis of DLBCL identifies immune environments associated with bispecific antibody response
1个月前
已关闭
A multicenter, randomized, double-blinded, placebo-controlled, phase Ⅲ study evaluating the efficacy and safety of Xeligekimab (GR1501) in patients with moderate-to-severe plaque psoriasis
1个月前
已完结
Antibody‑drug conjugates in prostate cancer: Emerging strategies to enhance therapeutic index and current clinical landscape (Review)
2个月前
已完结
Biomarkers in Prostate Cancer: A Review
2个月前
已关闭
Biomarkers for breast cancer immunotherapy: PD-L1, TILs, and beyond
3个月前
已完结
皖公网安备34019202002308
